The Transition From Sunitinib Monotherapy to Modern First-Line Tyrosine Kinase Inhibitor (TKI)-Containing Regimens in Metastatic Clear-Cell Renal Cell Carcinoma. (PubMed, Cureus) - Oct 2, 2026 - "Nivolumab plus cabozantinib improved median PFS [16.6 vs. 8.3 months; HR 0.51] and ORR (55.7% vs. 27.1%). Pembrolizumab plus axitinib improved 12-month OS (89.9% vs. 78.3%; HR 0.53), median PFS (15.1 vs. 11.1 months; HR 0.69), and ORR (59.3% vs. 35.7%). Lenvatinib plus pembrolizumab demonstrated durable benefit in CLEAR, with median PFS of 23.9 versus 9.2 months (HR 0.47), ORR of 71.3% versus 36.7%, and a final OS HR of 0.79. Benmelstobart plus anlotinib also improved median PFS (19.0 vs. 9.8 months; HR 0.53) and ORR (72% vs. 25%)...The included evidence supports the transition away from sunitinib as the preferred first-line treatment for most patients with advanced or metastatic clear-cell RCC. However, sunitinib remains an evidence-based option for selected patients, including those with contraindications to immune-checkpoint inhibition, some patients with favorable-risk disease, and those with limited access to combination therapy."
Journal • Monotherapy • Review • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor
|
|
Shruti Singh; Sravani Manda
|